[usPropHeader] Error loading user control: The file '/CMSWebParts/WK.HLRP/LNC/LNCProductHeader.ascx' does not exist.

Buy this Article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Aschenbrenner, Diane S. MS, APRN, BC

Abstract

* Three new drugs have been approved: golimumab (Simponi) for severe rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis; tolvaptan (Samsca) for hyponatremia associated with congestive heart failure, liver cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion; and iloperidone (Fanapt) for the treatment of schizophrenia in adults.

 

* Bevacizumab (Avastin), a monoclonal antibody, has been approved for a new indication-the treatment of glioblastoma multiforme, an aggressive form of brain cancer that continues to progress with conventional therapy.